Company intelligence / Profile preview
Haim Bio
Seoul, Seoul, South Koreaen.haimbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Haim Bio’s lead candidate, Starvanip, is a metabolism-based small molecule therapy targeting cancer cells by inhibiting ALDH and mitochondrial complex I. Phase 1 part 1 results were expected in late 2020; the company reports significant tumor reduction and increased cancer cell death with minimal toxicity to normal cells. Additional pipeline assets include a cancer stem cell inhibitor and an acidosis remover for combination therapies. The company is also exploring new substances as candidates for refractory/metastatic cancers[3].
- Therapeutic areas
- Oncology
- Modalities
- Small molecule (e.g., Starvanip, gossypol, phenformin hydrochloride)Combination therapy (e.g., gossypol + phenformin)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Joint venture Elysium Cell Bio USA established with A&P Partners for anti-coronavirus technology development; discussions ongoing with major South Korean pharmaceutical companies for future collaborations[2].
Beyond the preview
Go deeper on Haim Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haim Bio.